MA30768B1 - Methodes d'administration d'agents hypoglycemiques a longue duree d'action - Google Patents
Methodes d'administration d'agents hypoglycemiques a longue duree d'actionInfo
- Publication number
- MA30768B1 MA30768B1 MA31741A MA31741A MA30768B1 MA 30768 B1 MA30768 B1 MA 30768B1 MA 31741 A MA31741 A MA 31741A MA 31741 A MA31741 A MA 31741A MA 30768 B1 MA30768 B1 MA 30768B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- action
- long term
- hypoglycemic agents
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES MÉTHODES ET DES COMPOSITIONS PHARMACEUTIQUES DESTINÉES À L'ADMINISTRATION D'AGENTS HYPOGLYCÉMIQUES ET/OU D'AGONISTES DE GLP-1, CARACTÉRISÉES EN CE QU'ELLES PERMETTENT D'AUGMENTER ET/OU DE MAINTENIR LES VALEURS MOYENNES DE CONCENTRATION PLASMATIQUE MAXIMALE (CMAX) ET/OU DE SURFACE SOUS LA COURBE (AUC) DE L'AGENT HYPOGLYCÉMIQUE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82547206P | 2006-09-13 | 2006-09-13 | |
US86839106P | 2006-12-04 | 2006-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30768B1 true MA30768B1 (fr) | 2009-10-01 |
Family
ID=39184534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31741A MA30768B1 (fr) | 2006-09-13 | 2009-03-30 | Methodes d'administration d'agents hypoglycemiques a longue duree d'action |
Country Status (25)
Country | Link |
---|---|
US (3) | US8338369B2 (fr) |
EP (1) | EP2073834B1 (fr) |
JP (2) | JP5524620B2 (fr) |
KR (1) | KR101472601B1 (fr) |
CN (1) | CN103705911A (fr) |
AR (1) | AR062775A1 (fr) |
AU (1) | AU2007296499C1 (fr) |
BR (1) | BRPI0716765A8 (fr) |
CA (1) | CA2662622C (fr) |
CL (1) | CL2007002634A1 (fr) |
CR (1) | CR10684A (fr) |
EA (1) | EA017159B1 (fr) |
ES (1) | ES2442869T3 (fr) |
IL (1) | IL197448A (fr) |
JO (1) | JO2945B1 (fr) |
MA (1) | MA30768B1 (fr) |
MX (1) | MX2009002863A (fr) |
MY (1) | MY149911A (fr) |
NO (1) | NO20091266L (fr) |
NZ (1) | NZ575419A (fr) |
PE (2) | PE20121528A1 (fr) |
SG (2) | SG174770A1 (fr) |
TW (1) | TWI430806B (fr) |
WO (1) | WO2008033888A2 (fr) |
ZA (1) | ZA200901548B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE029798T2 (en) | 2005-11-04 | 2017-03-28 | Glaxosmithkline Llc | Methods of administering hypoglycemic agents |
US8748377B2 (en) * | 2008-12-10 | 2014-06-10 | Glaxosmithkline Llc | Pharmaceutical compositions |
US8691763B2 (en) | 2010-05-04 | 2014-04-08 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
WO2012080471A1 (fr) | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Compositions solides comprenant un agoniste de glp-1 et un sel de l'acide n-(8-(2-hydroxybenzoyl)amino)caprylique |
ES2612278T3 (es) | 2011-04-12 | 2017-05-16 | Novo Nordisk A/S | Derivados de GLP-1 doble-acilados |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
MY172578A (en) * | 2013-05-02 | 2019-12-03 | Novo Nordisk As | Oral dosing of glp-1 compounds |
PE20151770A1 (es) | 2013-05-28 | 2015-12-11 | Takeda Pharmaceutical | Compuesto peptidico |
EP3467106A4 (fr) | 2016-05-24 | 2020-02-26 | Takeda Pharmaceutical Company Limited | Composé peptidique |
EP3746111B1 (fr) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant |
AR125086A1 (es) * | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Composiciones que contienen análogos de incretina y usos de estas |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
ATE493998T1 (de) | 1996-08-08 | 2011-01-15 | Amylin Pharmaceuticals Inc | Pharmazeutische zusammensetzung mit einem exendin-4-peptid |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
JP2002523466A (ja) * | 1998-08-28 | 2002-07-30 | イーライ・リリー・アンド・カンパニー | インスリン向性ペプチドの投与方法 |
DE60006100T2 (de) * | 1999-05-17 | 2004-07-01 | Conjuchem, Inc., Montreal | Lang wirkende insulinotrope peptide |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
PL209550B1 (pl) | 2000-12-07 | 2011-09-30 | Lilly Co Eli | Heterogenne białko fuzyjne, kompozycja farmaceutyczna do leczenia pacjentów z cukrzycą insulinoniezależną i kompozycja do leczenia pacjentów z otyłością |
JP2004521093A (ja) * | 2000-12-13 | 2004-07-15 | イーライ・リリー・アンド・カンパニー | グルカゴン様インスリン刺激性ペプチドを用いる長期治療計画 |
AU2002308706A1 (en) * | 2001-06-01 | 2002-12-16 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
AU2002322403A1 (en) * | 2001-08-23 | 2003-03-10 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
WO2003033671A2 (fr) | 2001-10-18 | 2003-04-24 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
EP1463752A4 (fr) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Proteines de fusion d'albumine |
EP1997829A1 (fr) * | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
WO2003058203A2 (fr) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Analogues de peptide-1 de type glucagon d'extension |
CA2513213C (fr) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
SI1689757T1 (sl) * | 2003-11-12 | 2015-01-30 | Sino-Med International Alliance, Inc. | Heterociklične spojine boronske kisline |
EP1704998B1 (fr) * | 2004-01-13 | 2011-04-20 | Asahi Glass Company, Limited | Lamelle multicouche |
SI1729795T1 (sl) | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
JP2008501765A (ja) * | 2004-06-11 | 2008-01-24 | ノボ ノルディスク アクティーゼルスカブ | Glp−1アゴニストを用いた薬剤誘発性肥満の中和 |
HUE029798T2 (en) * | 2005-11-04 | 2017-03-28 | Glaxosmithkline Llc | Methods of administering hypoglycemic agents |
EP2021014A1 (fr) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Modulateurs des récepteurs de glp-1 à libération prolongée |
-
2007
- 2007-09-11 CL CL200702634A patent/CL2007002634A1/es unknown
- 2007-09-11 TW TW096133808A patent/TWI430806B/zh not_active IP Right Cessation
- 2007-09-11 PE PE2012001061A patent/PE20121528A1/es not_active Application Discontinuation
- 2007-09-11 PE PE2007001215A patent/PE20080840A1/es not_active Application Discontinuation
- 2007-09-11 JO JO2007382A patent/JO2945B1/en active
- 2007-09-12 CA CA2662622A patent/CA2662622C/fr not_active Expired - Fee Related
- 2007-09-12 ES ES07842306.8T patent/ES2442869T3/es active Active
- 2007-09-12 AR ARP070104049A patent/AR062775A1/es not_active Application Discontinuation
- 2007-09-12 EA EA200970274A patent/EA017159B1/ru not_active IP Right Cessation
- 2007-09-12 WO PCT/US2007/078226 patent/WO2008033888A2/fr active Application Filing
- 2007-09-12 MY MYPI20090993A patent/MY149911A/en unknown
- 2007-09-12 US US12/441,152 patent/US8338369B2/en not_active Expired - Fee Related
- 2007-09-12 EP EP07842306.8A patent/EP2073834B1/fr active Active
- 2007-09-12 SG SG2011063856A patent/SG174770A1/en unknown
- 2007-09-12 MX MX2009002863A patent/MX2009002863A/es active IP Right Grant
- 2007-09-12 JP JP2009528440A patent/JP5524620B2/ja active Active
- 2007-09-12 SG SG10201501749WA patent/SG10201501749WA/en unknown
- 2007-09-12 NZ NZ575419A patent/NZ575419A/en not_active IP Right Cessation
- 2007-09-12 KR KR1020097007414A patent/KR101472601B1/ko active Protection Beyond IP Right Term
- 2007-09-12 CN CN201410014248.3A patent/CN103705911A/zh active Pending
- 2007-09-12 AU AU2007296499A patent/AU2007296499C1/en not_active Ceased
- 2007-09-12 BR BRPI0716765A patent/BRPI0716765A8/pt not_active Application Discontinuation
-
2009
- 2009-03-04 ZA ZA2009/01548A patent/ZA200901548B/en unknown
- 2009-03-05 IL IL197448A patent/IL197448A/en active IP Right Grant
- 2009-03-23 CR CR10684A patent/CR10684A/es not_active Application Discontinuation
- 2009-03-26 NO NO20091266A patent/NO20091266L/no not_active Application Discontinuation
- 2009-03-30 MA MA31741A patent/MA30768B1/fr unknown
-
2012
- 2012-06-12 US US13/494,253 patent/US20130005652A1/en not_active Abandoned
-
2013
- 2013-07-19 US US13/946,296 patent/US20140066371A1/en not_active Abandoned
-
2014
- 2014-04-10 JP JP2014081275A patent/JP5753924B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30768B1 (fr) | Methodes d'administration d'agents hypoglycemiques a longue duree d'action | |
ES2526463T3 (es) | Exendina para el tratamiento de la diabetes y la reducción del peso corporal | |
HK1050477A1 (en) | Use of exendins and agonists thereof for the treatment of hypertriglyceridemia. | |
WO2006089114A3 (fr) | Procedes et compositions pour le traitement d'un sujet souffrant d'un etat a mediation assuree par la toxine de l'anthrax | |
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
HUP0301405A2 (hu) | Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények | |
CO6440528A2 (es) | Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico. | |
WO2009109927A3 (fr) | Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer | |
GT200600004A (es) | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1 | |
DE602006014990D1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
AR043258A1 (es) | Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica | |
WO2010036918A3 (fr) | Récepteur intracellulaire d'adn | |
EA200901112A1 (ru) | Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу | |
EA200800950A1 (ru) | Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо | |
CL2009000985A1 (es) | Composicion oftalmica que comprende entre 0,16 y 0,19% p/v de un galactomanano, alrededor de 0,7% p/v de un borato, cis-diol y menos de 5 ppm de concentracion de cationes divalentes; y su uso para lubricar el ojo. | |
MX2010005013A (es) | Composiciones intranasales. | |
MX2007010295A (es) | Composiciones oftalmologicas novedosas y metodo para su uso. | |
WO2007056236A3 (fr) | Methodes de traitement anticancereux avec des formulations d'un compose de platine a base de lipides administree par voie intraveineuse | |
AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
WO2008128191A3 (fr) | Formes dosifiees orales de cephalotaxine | |
CL2009000986A1 (es) | Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma | |
AR061155A1 (es) | Preparaciones liofilizadas de pantoprazol sodico para inyeccion | |
AR052015A1 (es) | Agente para la profilaxis o tratamiento del sindrome metabolico | |
PE20030277A1 (es) | Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa | |
AR029557A1 (es) | Composicion para el uso en el tratamiento o la prevencion de la mastitis, y uso de oxazolidinona para la fabricacion de un medicamento para el tratamiento o la prevencion de la mastitis |